Zai Lab (HKSE:09688) Change In Receivables : HK$-132 Mil (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Zai Lab Change In Receivables?

Zai Lab's change in receivables for the quarter that ended in Mar. 2024 was HK$-83 Mil. It means Zai Lab's Accounts Receivable increased by HK$83 Mil from Dec. 2023 to Mar. 2024 .

Zai Lab's change in receivables for the fiscal year that ended in Dec. 2023 was HK$-138 Mil. It means Zai Lab's Accounts Receivable increased by HK$138 Mil from Dec. 2022 to Dec. 2023 .

Zai Lab's Accounts Receivable for the quarter that ended in Mar. 2024 was HK$473 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Zai Lab's Days Sales Outstanding for the three months ended in Mar. 2024 was 63.27.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Zai Lab's liquidation value for the three months ended in Mar. 2024 was HK$3,824 Mil.

Zai Lab Change In Receivables Historical Data

The historical data trend for Zai Lab's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zai Lab Change In Receivables Chart

Zai Lab Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-73.32

-75.81

-400.64

195.69

-138.14

Zai Lab Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															-89.88	-79.32	24.98	5.45	-82.67

Zai Lab Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$-132 Mil.

Zai Lab (HKSE:09688) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Zai Lab's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	472.681	/	681.767	*	91
=	63.27

2. In Ben Graham's calculation of liquidation value, Zai Lab's accounts receivable are only considered to be worth 75% of book value:

Zai Lab's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	5091.052	-	1770.095	+	0.75 * 472.681	+	0.5 * 296.108
=	3,824

Zai Lab Change In Receivables Related Terms

Thank you for viewing the detailed overview of Zai Lab's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Zai Lab (HKSE:09688) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zai Lab Ltd (HKSE:09688) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

ZLAB:USA ZLAB:Mexico 1ZLB:Germany

Address

4560 Jinke Road, Jinchuang Plaza, Building 1, 4th Floor, Pudong, Shanghai, CHN, 201210

Website

https://www.zailaboratory.com

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatment across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.

Zai Lab (HKSE:09688) Headlines

No Headlines